TY - JOUR
T1 - Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups
AU - Attarbaschi, Andishe
AU - Morak, Maria
AU - Cario, Gunnar
AU - Cazzaniga, Giovanni
AU - Ensor, Hannah M.
AU - Te Kronnie, Truus
AU - Bradtke, Jutta
AU - Mann, Georg
AU - Vendramini, Elena
AU - Palmi, Chiara
AU - Schwab, Claire
AU - Russell, Lisa J.
AU - Schrappe, Martin
AU - Conter, Valentino
AU - Mitchell, Christopher D.
AU - Strehl, Sabine
AU - Zimmermann, Martin
AU - Pötschger, Ulrike
AU - Harrison, Christine J.
AU - Stanulla, Martin
AU - Panzer-grümayer, Renate
AU - Haas, Oskar A.
AU - Moorman, Anthony V.
PY - 2012/9/1
Y1 - 2012/9/1
N2 - The prognostic relevance of CRLF2 -rearrangements in childhood acute B-cell precursor lymphoblastic leukaemia (ALL), was assessed by a comparative analysis of 114 non-Down-syndrome patients (99 P2RY8-CRLF2+ , 15 IGH@-CRLF2+ ), 76 from the AIEOP-BFM ALL 2000 and 38 from the MRC ALL97 trials. The 6-year cumulative relapse incidence of P2RY8-CRLF2+ patients treated on the two trials was not statistically different: 0·37 ± 0·06 vs. 0·25 ± 0·08 (P = 0·194). In contrast, 0/9 IGH@-CRLF2+ AIEOP-BFM, but 5/6 ALL97 patients relapsed. Conclusively, P2RY8-CRLF2+ patients had an intermediate protocol-independent outcome while the different prognosis of IGH@-CRLF2+ patients could be related to the different structures of the applied treatment protocols.
AB - The prognostic relevance of CRLF2 -rearrangements in childhood acute B-cell precursor lymphoblastic leukaemia (ALL), was assessed by a comparative analysis of 114 non-Down-syndrome patients (99 P2RY8-CRLF2+ , 15 IGH@-CRLF2+ ), 76 from the AIEOP-BFM ALL 2000 and 38 from the MRC ALL97 trials. The 6-year cumulative relapse incidence of P2RY8-CRLF2+ patients treated on the two trials was not statistically different: 0·37 ± 0·06 vs. 0·25 ± 0·08 (P = 0·194). In contrast, 0/9 IGH@-CRLF2+ AIEOP-BFM, but 5/6 ALL97 patients relapsed. Conclusively, P2RY8-CRLF2+ patients had an intermediate protocol-independent outcome while the different prognosis of IGH@-CRLF2+ patients could be related to the different structures of the applied treatment protocols.
U2 - 10.1111/j.1365-2141.2012.09221.x
DO - 10.1111/j.1365-2141.2012.09221.x
M3 - Article
SN - 0007-1048
VL - 158
SP - 772
EP - 777
JO - British journal of haematology
JF - British journal of haematology
IS - 6
ER -